Drug intelligence / Profile preview

cetrorelix + clomiphene

Development stage: Unknown
Lead developer: Merck KGaA
Modality: Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination protocol used in assisted reproduction therapy, specifically for controlled ovarian stimulation. This approach combines cetrorelix, a GnRH antagonist that prevents premature LH surges, with clomiphene citrate, an ovulatory stimulant. The protocol typically involves starting clomiphene early in the menstrual cycle, followed by gonadotropins, with cetrorelix added when the dominant follicle reaches sufficient size. This combination is considered a "mild stimulation" or "friendly IVF" protocol aimed at reducing side effects and costs compared to traditional IVF approaches.

Targets

ER (Estrogen receptor)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on cetrorelix + clomiphene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetrorelix + clomiphene.

Explore the full profile